サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1650737

RNA解析/トランスクリプトミクスの世界市場

RNA Analysis / Transcriptomics

出版日
ページ情報
英文 504 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
RNA解析/トランスクリプトミクスの世界市場
出版日: 2025年02月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 504 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

RNA解析トランスクリプトミクスの世界市場は2030年までに190億米ドルに達する見込み

2024年に89億米ドルと推定されるRNA解析トランスクリプトミクスの世界市場は、2030年には190億米ドルに達し、分析期間2024-2030年のCAGRは13.4%で成長すると予測されます。RNA解析トランスクリプトミクス試薬／消耗品は、本レポートで分析したセグメントの1つであり、分析期間終了までにCAGR 14.5％を記録し、97億米ドルに達すると予測されます。RNA解析トランスクリプトミクス機器セグメントの成長率は、分析期間でCAGR 11.9％と推定されます。

米国市場は33億米ドル、中国はCAGR14.4％で成長予測

米国のRNA解析トランスクリプトミクス市場は、2024年に33億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.5％と13.3％と予測されています。欧州では、ドイツがCAGR約13.2%で成長すると予測されています。

世界のRNA解析トランスクリプトミクス市場- 主要動向と促進要因のまとめ

トランスクリプトミクスとしても知られるRNA解析は、細胞や生物体内のRNA分子の研究に焦点を当てた、分子生物学において強力かつ不可欠な分野です。トランスクリプトミクスは、DNAとタンパク質の中間体であるRNA転写物の量と配列を調べることにより、遺伝子発現と制御に関する洞察を提供します。この解析は、細胞機能の理解、疾患のバイオマーカーの同定、潜在的な治療標的の発見に極めて重要です。トランスクリプトミクスでは、RNA配列決定（RNA-Seq）、マイクロアレイ、定量的PCR（qPCR）などの手法が、異なる条件や開発段階におけるRNAレベルの測定や比較に一般的に用いられています。これらの方法により、研究者は遺伝子発現の包括的なプロファイルを構築し、生物学的プロセスや疾病メカニズムの複雑さに光を当てることができます。

技術の進歩は、RNA解析の能力と応用を著しく向上させました。ハイスループットシーケンス技術、特にRNA-Seqは、ゲノムワイドなスケールでRNA転写産物の正確かつ包括的な定量化を可能にし、トランスクリプトミクスに革命をもたらしました。RNA-Seqは、従来の方法と比較してトランスクリプトームのより詳細で偏りのないビューを提供し、新規転写産物、スプライスバリアント、ノンコーディングRNAの検出を可能にします。さらに、シングルセルRNAシーケンス（scRNA-Seq）は、単一細胞レベルでの遺伝子発現解析を可能にする革新的な技術として登場し、細胞の不均一性と細胞プロセスのダイナミクスをこれまでにない解像度で明らかにしています。計算ツールやバイオインフォマティクスの進歩もトランスクリプトミクスにおいて重要な役割を果たし、データ解析、統合、解釈に必要な枠組みを提供することで、研究者は複雑なデータセットから意味のある生物学的洞察を導き出すことができるようになりました。

RNA解析/トランスクリプトミクス市場の成長は、個別化医療に対する需要の増加、シーケンス技術の進歩、慢性疾患やがんの有病率の上昇など、いくつかの要因によって牽引されています。個人の遺伝子プロファイルに基づいて治療をオーダーメイドすることを目指す個別化医療へのシフトは、疾患特異的バイオマーカーや治療標的を特定するための包括的トランスクリプトーム解析の必要性に拍車をかけています。シーケンシング技術の絶え間ない改善により、精度、スループット、費用対効果が向上し、トランスクリプトーム研究がより身近なものとなり、より幅広い応用が可能となりました。さらに、慢性疾患やがんの罹患率の上昇により、これらの病態の分子的背景を理解することに焦点が当てられるようになり、研究および臨床の場におけるトランスクリプトミクスの導入が推進されています。ゲノミクス研究に対する政府の取り組みや資金援助、学術機関と製薬会社の協力関係も、市場の拡大に寄与しています。その結果、RNA解析/トランスクリプトミクス分野は、現在進行中の技術革新と応用により、生物学の理解を深め、ヘルスケアの転帰を改善することが期待され、大きく成長する態勢が整っています。

セグメント

製品（試薬／消耗品、機器、サービス、ソフトウェア）;テクノロジー（ポリメラーゼ連鎖反応、シーケンス、マイクロアレイ、RNA干渉）;アプリケーション（創薬、トキシコゲノミクス、臨床診断、比較トランスクリプトミクス）

調査対象企業の例（注目の合計115社）

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • Analytik Jena AG
  • Ambry Genetics
  • Advanced Cell Diagnostics, Inc.
  • Bioneer Corporation
  • BioChain Institute, Inc.
  • Akoya Biosciences, Inc.
  • Acobiom
  • ADS Biotec, Inc.
  • BGI Genomics Co Ltd.
  • 10X Genomics
  • Biois Co Ltd
  • Bertin Technologies, Sas

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP15286

Global RNA Analysis / Transcriptomics Market to Reach US$19.0 Billion by 2030

The global market for RNA Analysis / Transcriptomics estimated at US$8.9 Billion in the year 2024, is expected to reach US$19.0 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2024-2030. RNA Analysis / Transcriptomics Reagents / Consumables, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$9.7 Billion by the end of the analysis period. Growth in the RNA Analysis / Transcriptomics Instruments segment is estimated at 11.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.3 Billion While China is Forecast to Grow at 14.4% CAGR

The RNA Analysis / Transcriptomics market in the U.S. is estimated at US$3.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.5% and 13.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.2% CAGR.

Global RNA Analysis / Transcriptomics Market - Key Trends & Drivers Summarized

RNA analysis, also known as transcriptomics, is a powerful and essential field in molecular biology that focuses on the study of RNA molecules within a cell or organism. Transcriptomics provides insights into gene expression and regulation by examining the quantity and sequences of RNA transcripts, which are the intermediates between DNA and proteins. This analysis is crucial for understanding cellular functions, identifying biomarkers for diseases, and discovering potential therapeutic targets. Techniques such as RNA sequencing (RNA-Seq), microarrays, and quantitative PCR (qPCR) are commonly used in transcriptomics to measure and compare RNA levels across different conditions or stages of development. These methods allow researchers to construct comprehensive profiles of gene expression, shedding light on the complexities of biological processes and disease mechanisms.

Technological advancements have significantly enhanced the capabilities and applications of RNA analysis. High-throughput sequencing technologies, particularly RNA-Seq, have revolutionized transcriptomics by enabling the precise and comprehensive quantification of RNA transcripts on a genome-wide scale. RNA-Seq provides a more detailed and unbiased view of the transcriptome compared to traditional methods, allowing for the detection of novel transcripts, splice variants, and non-coding RNAs. Additionally, single-cell RNA sequencing (scRNA-Seq) has emerged as a transformative technique that allows for the analysis of gene expression at the single-cell level, revealing cellular heterogeneity and the dynamics of cellular processes with unprecedented resolution. Advances in computational tools and bioinformatics have also played a crucial role in transcriptomics, providing the necessary frameworks for data analysis, integration, and interpretation, thus enabling researchers to derive meaningful biological insights from complex datasets.

The growth in the RNA analysis/transcriptomics market is driven by several factors, including the increasing demand for personalized medicine, advancements in sequencing technologies, and the rising prevalence of chronic diseases and cancer. The shift towards personalized medicine, which aims to tailor treatments based on an individual’s genetic profile, has spurred the need for comprehensive transcriptomic analysis to identify disease-specific biomarkers and therapeutic targets. Continuous improvements in sequencing technologies, resulting in higher accuracy, throughput, and cost-effectiveness, have made transcriptomic studies more accessible and feasible for a broader range of applications. Additionally, the rising incidence of chronic diseases and cancer has increased the focus on understanding the molecular underpinnings of these conditions, driving the adoption of transcriptomics in research and clinical settings. Government initiatives and funding for genomics research, along with collaborations between academic institutions and pharmaceutical companies, are also contributing to the market's expansion. As a result, the RNA analysis/transcriptomics field is poised for significant growth, with ongoing innovations and applications promising to enhance our understanding of biology and improve healthcare outcomes.

SCOPE OF STUDY:

The report analyzes the RNA Analysis / Transcriptomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Reagents / Consumables, Instruments, Services, Software); Technology (Polymerase Chain Reaction, Sequencing, Microarray, RNA Interference); Application (Drug Discovery, Toxicogenomics, Clinical Diagnostics, Comparative Transcriptomics)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 115 Featured) -

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • Analytik Jena AG
  • Ambry Genetics
  • Advanced Cell Diagnostics, Inc.
  • Bioneer Corporation
  • BioChain Institute, Inc.
  • Akoya Biosciences, Inc.
  • Acobiom
  • ADS Biotec, Inc.
  • BGI Genomics Co Ltd.
  • 10X Genomics
  • Biois Co Ltd
  • Bertin Technologies, Sas

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • RNA-Oriented Projects Set to Increase
    • Competition
    • RNA Analysis / Transcriptomics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • What is RNA-Seq Technology?
    • A Prelude to Transcriptomics Technologies
    • Global Market Prospects & Outlook
    • PCR Emerges as the Leading Technology
    • Drug Discovery Segment Poised to Lead the Global Market
    • North America Emerges as the Major Regional Market
    • World Brands
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Trend Towards Personalized Medicine Fuels Market Growth
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
    • Transcriptomics Assume Critical Importance amid Growing Prevalence of Chronic Diseases
    • World Diabetes and Population Statistics (2021, 2030 & 2045)
    • World Diabetes Prevalence (2000-2045)
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Burden of Neurological Diseases: Deaths Per 100,000 Population due to Neurological Conditions in Select Countries
    • Transcriptomics Applications in Disease and Diagnostic Profiling
    • Increasing PCR Applications in Biotechnology Sector
    • Progressive Growth of Omics Technologies: Opportunity for RNA Analysis/Transcriptomics Market
    • The Growing Role of Transcriptomics in Oncology
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • RNA Sequencing Critical for Cancer and Rare Diseases
    • Bulk-Tissue RNA Sequencing and Single-Cell RNA Sequencing for Cardiovascular Research
    • Bulk RNA Sequencing
    • Single-Cell Sequencing
    • Spatial Transcriptomics
    • Single-Cell RNA-seq Technologies Witness Steady Growth
    • The Evolution of scRNA-seq
    • Growth of Long-Read Transcriptome Sequencing
    • scRNA-seq for Autoimmune Inflammatory Rheumatic Diseases
    • SPLiTseq Beneficial for Understanding Cause of Disease
    • Gene Expression Microarray Technology Gains Ground
    • Microfluidics-based Droplet Technologies Demonstrate Growth
    • inDrops Approach Exhibits Growth
    • Spatial Transcriptomics Market Witnesses Significant Growth
    • Spatial Transcriptomic Data Analysis
    • Next Generation Sequencing Offers Increased Accuracy for Transcriptomics Activity
    • Single-cell NGS Witnesses Rapid Growth
    • RNA Sequencing Benefits Fuel Market Prospects
    • Blood Transcriptome Sequencing for Identifying Rare-Disease Genes
    • Rising Focus on Toxicogenomics: Potential for RNA Analysis/Transcriptomics Markets
    • Growing R&D Spending in Pharma and Biotechnology Sectors Presents Opportunities
    • Pharmaceutical R&D Spending Worldwide (USD Billion) for 2015-2025
    • Technological Advancements & Innovations Fuel Market Growth
    • Sci-Plex - A New Technique to Profile Gene Expression within Single Cells
    • Introduction of Oxford Nanopore's Innovative Portable Sequencer for Sequencing Long Reads and RNA Molecules Improves Transcriptomic Analysis
    • RNA-Combine, a Toolkit for More Comprehensively Analyzing Transcriptome Data
    • Aging Demographics Present Opportunities for Transcriptomics Technologies
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Challenges Facing RNA/Transcriptomics Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for RNA Analysis / Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for RNA Analysis / Transcriptomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Reagents / Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Reagents / Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Reagents / Consumables by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Polymerase Chain Reaction by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Microarrays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for RNA Interference by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for RNA Interference by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Toxicogenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Toxicogenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Toxicogenomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Comparative Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Comparative Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Comparative Transcriptomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 40: World RNA Analysis / Transcriptomics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA Analysis / Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • JAPAN
    • TABLE 59: Japan Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • CHINA
    • RNA Analysis / Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • EUROPE
    • RNA Analysis / Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for RNA Analysis / Transcriptomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • FRANCE
    • TABLE 89: France Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • GERMANY
    • TABLE 98: Germany Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • TABLE 116: UK Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • RNA Analysis / Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of World 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of World 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of World 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2025 & 2030

IV. COMPETITION